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Abstract
Purpose Literature data indicate that the proportion of
patients with recent hip fracture who receive a prescription
for anti-osteoporotic drugs is low and does not seem to
increase over time. This study aimed to obtain data on the
prescription for anti-osteoporotic drugs in Italian patients
discharged after a recent hip fracture and to assess which
variables could have influenced the decision for prescribing
osteoporosis medication.
Methods A total of four Italian centres located in four
different geographical areas (Siena, Verona, Naples and
Palermo) participated in this retrospective study. In
each centre, experienced clinicians gathered the data of
up to 200 consecutive patients discharged after a recent
low-trauma hip fracture. The analysis was carried out
on 697 patients (540 women and 157 men; mean age
81.9 ± 8.6 years).
Results The percentage of patients who were receiving any
type of treatment for osteoporosis before the hip fracture
was 8.8% (ranging from 2.4% in Naples to 17.4% in
Verona). After the index hip fracture, only 23.2% of
patients (namely 10.5% of men and 27.2% of women)
received prescription for any pharmacological treatments
for osteoporosis. Both female gender and previous use of
medications for osteoporosis were positively associated
with the likelihood of receiving prescription for anti-os-
teoporotic treatment at discharge.
Conclusions This study showed that less than 25% of the
elderly Italian patients discharged after a hip fracture
received a prescription for any type of treatment for
osteoporosis and highlights the urgent need for imple-
menting new strategies in the management of hip fracture
patients.
Keywords Hip fracture  Anti-osteoporotic drugs 
Comorbidities  Ca/vitamin D supplements
Introduction
Osteoporosis is a major medical problem which has a
remarkable financial impact on society. Hip fracture is
considered the most serious complication of osteoporosis
because of the disability, morbidity, mortality and cost to
which it contributes [1, 2]. The bulk of non-traumatic hip
fractures is due to both osteoporosis-related bone loss and
age-related deterioration of bone quality [3]. In Italy,
90,000 hip fractures per year are reported in subjects aged
50 years or over with a growing trend [4]. Patients who
suffer their first hip fracture are at greater risk of recurrent
vertebral and non-vertebral osteoporotic fractures. In par-
ticular, in these patients the risk of a second hip fracture is
as much as six times greater and with the risk of a non-hip
fracture being nine to fifteen times greater, with 10%
having another hip fracture within one year [5, 6]. At
present, there is a growing conviction that focusing atten-
tion on patients with hip fractures may be of crucial
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importance in reducing the burden of osteoporosis and
subsequent fragility fractures [7–9]. Therefore, current
national and international guidelines recommend the use of
pharmacological treatments after hip fracture [10, 11].
Moreover, the results of several studies showed a decreased
mortality rate in patients who were managed with anti-
osteoporotic drugs as compared with those who were not
[12–14]. In particular, in the HORIZON study [13] hip
fracture patients were randomly assigned to receive annu-
ally zoledronic acid either by intravenous infusion or a
placebo infusion; both groups received both oral calcium
and vitamin D daily. In this latter study, the median follow-
up was 1.9 years and in the zoledronic acid group there was
a relative risk reduction of 28% for death from any causes
[13]. Notwithstanding, many studies have reported that a
significant proportion of hip fracture patients do not receive
any treatment for osteoporosis. In fact, literature data
indicate that the proportion of patients with recent hip
fracture who receive a prescription of anti-osteoporotic
drugs varies between 15 and 40% and does not seem to
increase over time in any Western countries [15]. On the
contrary, in more recent years the use of bisphosphonates,
the most commonly used group of anti-osteoporotic drugs
after hip fracture, decreased significantly over the years in
both the USA and some European countries [15]. At pre-
sent, in Italy very few data are available on the percentage
of patients with recent hip fracture who are receiving
prescriptions for anti-osteoporotic drugs. The aim of this
study was twofold: (1) to obtain data on the prescription for
anti-osteoporotic drugs in patients discharged after a recent
hip fracture and (2) to assess which variables (comorbidi-
ties, age, etc.) could have influenced the decision for pre-
scribing osteoporosis medication.
Materials and methods
A total of four Italian centres (Departments of Orthopedics
and Rehabilitation) located in academic and non-academic
general hospitals over four different geographical areas
(Siena, Verona, Naples and Palermo) were invited to par-
ticipate in this study. In each centre, experienced clinicians
gathered the data of up to 200 consecutive patients, aged
65 years or over, discharged from 1 January 2014 to 31
December 2014 after a recent low-trauma hip fracture. Low
trauma fractures were either spontaneous or caused by
minimal trauma (trauma equal to or less than a fall from a
standing position). The pathological hip fractures due to
primary or metastatic bone cancer, multiple myeloma,
Paget’s disease of bone or primary hyperparathyroidism
were excluded. The clinicians of each centre, by reviewing
the clinical documents of patients, collected demographic
data and information concerning the type of hip fracture,
the type of surgical management of hip fracture, smoking
habits and history of previous fragility fractures. The his-
tory of previous fragility fractures was ascertained both by
self reporting (patient and/or caregiver) and, when avail-
able, from the assessment of health documentation. At each
centre, hip fractures were classified on the basis of preop-
erative radiographs and surgical reports as cervical (or
medial or intra-capsular) and trochanteric fractures (or
lateral or extra-capsular). By reviewing clinical documents,
information was also collected concerning the more fre-
quent comorbidities and the use of medications known to
interfere with bone metabolism such as glucocorticoids,
diuretics, insulin and oral antidiabetic drugs, anticoagu-
lants, proton pump inhibitors, antihypertensives and
antidepressants. Detailed information on osteoporosis
medications, either anti-osteoporotic drugs or calcium/vi-
tamin D supplementation, taken in the 12 months before
the index hip fracture, was also gathered. Concerning
osteoporosis medications after index hip fracture, the
clinicians of each centre considered not only those pre-
scribed at discharge from orthopaedic wards but also those
prescribed during the following rehabilitation period by
other physicians. When necessary the clinical document
information was confirmed by telephone to patients/care-
givers and GPs. Study protocol was prepared according to
the Declaration of Helsinki and subsequent integrations
and was approved by the local ethical committee of each
centre.
Statistical analysis
Continuous variables normally distributed were reported as
the mean and standard deviation, while those not normally
distributed were reported as the median and interquartile
range. Categorical variables were reported as proportions
and percentages. Statistical comparisons across groups
were carried out by Chi-square test or Fisher’s exact test as
appropriate. Conditional logistic regression analysis was
used in order to evaluate any possible associations between
study variables and the prescription of osteoporosis medi-
cations. All statistical analyses were carried out by using
statistical software (SPSS 10.1).
Results
Overall, the four participating centres enrolled 731
patients, but 34 were discarded for incomplete information
on clinical data and pharmacological treatment. Therefore,
the analysis was carried out on the remaining 697 patients.
The distribution of demographic and clinical characteristics
of the 697 hip fracture patients is shown in Table 1. The
mean age of study population was high (81.9 ± 8.6 years)
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and as expected there was a predominance of females
(77.5%) with respect to males (22.5%), so that the ratio
between the two sexes was 3.4. No significant differences
in clinical and demographic parameters were observed
among the four groups. Concerning the management of hip
fractures, 57.9% of hip fracture patients underwent
osteosynthesis procedure, whereas 32.2% underwent a
prosthetic replacement and the remaining 9.9% received a
conservative treatment. The most prevalent hip fractures
were cervical (43%). Overall, 28.7% of hip fracture
patients had a history of previous fragility fracture with the
hip being the most prevalent site (10.2% of patients).
Almost all patients presented comorbidities and were
taking several medications. Table 2 shows the distribution
of reported comorbidities and of medications taken at the
moment of the hip fracture both altogether and grouped by
the participating centres. As expected, the more frequent
comorbidities were: cardiovascular diseases (71.6%),
dementia (38%), diabetes (23%), cancer (12.5%) and
COPD (11.3%).
Figure 1 illustrates the distribution of patients by the use
of drugs for osteoporosis before hip fracture and at dis-
charge from orthopaedic wards or rehabilitation facilities.
The patients were also stratified by the four participating
centres. Overall, the percentage of patients who were
receiving any type of treatment for osteoporosis before the
hip fracture was 8.8% (ranging from 2.4% in Naples to
17.4% in Verona). No significant difference in the use of
drugs for osteoporosis before hip fracture was found
between the patients with or without a history of fragility
fractures; moreover, only 6 of 56 (10.7%) with previous
hip fracture were receiving anti-osteoporotic medications
(data not shown). After the index hip fracture 23.2% of
patients received prescription for pharmacological treat-
ment for osteoporosis, whereas the remaining patients
(76.8%) did not receive any prescriptions. Considering
separately men and women, we found that 27.2% of
women and 10.5% of men were prescribed for anti-osteo-
porotic treatments at discharge. Important differences were
observed among the four participating centres. Strikingly,
at the Siena centre the proportion of patients who received
anti-osteoporosis medication was lower after than before
the index hip fracture (9.1 vs 10.8%) (Fig. 1).
Moreover, the majority of hip fracture patients were
only prescribed supplementation with calcium and/or
vitamin D. Figure 2 shows the distribution of patients
treated with the more common drugs for osteoporosis
before and after the hip fracture. In particular, the pre-
scription of bisphosphonates markedly increased while
remaining low (4.7% after hip fracture vs 2.7% before).
Moreover, the prescription of denosumab, practically non-
existent before hip fracture, reached the 4% after hip
fracture (Fig. 2). Only one patient was on treatment with
teriparatide before hip fracture, and six patients were pre-
scribed with teriparatide after the hip fracture (Fig. 2).
Logistic regression analysis showed that only female
gender and previous use of anti-osteoporosis medications
were positively associated with the likelihood of receiving
prescription for anti-osteoporotic treatment at discharge
(Table 3). Instead, the prescription of anti-osteoporotic
treatments was seen not to be influenced by either age or
previous fractures.
Discussion
This study provides relevant information on the current
management of elderly Italian patients with a recent hip
fracture. In particular, this study showed that less than 10%
of the elderly Italian patients discharged after a hip fracture
were receiving treatments for osteoporosis before the
fracture. Even more significant is the finding that more than
75% of patients were discharged without receiving pre-
scription for any pharmacological treatment for osteo-
porosis and less than 10% received prescription for
teriparatide or anticatabolic drugs (i.e. denosumab and
bisphosphonates).
Our results seem to be in agreement with most of the
relevant studieswhich reported that the rate of treatmentwith
anti-osteoporosis drugs is very low, ranging from 5 to 50%.
Table 1 Distribution of demographic and clinical characteristics of 697 elderly patients with hip fractures
All patients Siena Palermo Verona Naples
Number (male/female) 697 (540/157) 249 (187/62) 100 (80/20) 143 (111/32) 205 (162/43)
Age (years) 81.3 ± 8.6 83.6 ± 7.8 81.4 ± 8.8 83.7 ± 8.6 78.9 ± 8.4
Weight (kg) 65.1 ± 11.9 63.0 ± 13.5 62.5 ± 12.1 67.0 ± 10.2 69.6 ± 10.8
Height (cm) 161.5 ± 8.2 161.3 ± 8.3 159.2 ± 7.1 163.2 ± 8.6 –
Age at menopause (years) 49.5 ± 4.9 42.7 ± 13.4 50.5 ± 4.2 49.2 ± 3.9 47.9 ± 7.9
Number of children 1.7 ± 1.0 1.9 ± 1.0 1.5 ± 1.0 1.8 ± 0.9 2.4 ± 0.5
Patient’s history of fracture, n/total n (%) 187/697 (26.8) 59/243 (23.7) 13/100 (13) 87/143 (60.8) 28/205 (13.7)
Smoking, n/total n (%) 79/697 (11.3) 9/249 (3.6) 16/100 (16) 51/143 (35.7) 3/205 (1.5)
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In particular, the percentage of hip fracture patients who
received prescription for anti-osteoporosis drugs was 19% in
the study by Gardner et al. [16] and 15% in the study by
Panneman et al. [17]. A large study carried out in Belgian
patients who had sustained hip fracture reported that only 6%
received treatment [8]. Moreover, this latter study also
reported that of the patients whowere treated, only 41%were
continuing with their treatment by the end of the first year,
and fewer than half were found to be compliant [8]. A recent
cross-national study byKimet al. [15] reported that the use of
osteoporosis medications after hospitalization for hip frac-
ture ranged from11% in theUSA to 38% inKorea. This latter
study also reported that in the USA the proportion of patients
who received an osteoporosis medication was lower after the
index hip fracture than before [15]. Moreover, several
studies carried out in both the USA and Europe reported that
over the past decade there was a significant decrease in the
rate of osteoporosis medication after hip fracture, whichmay
be related to concerns over potential side effects of
bisphosphonates [15, 18]. The reasons for the gap between
national and international evidence-based treatment guide-
lines [10, 19] and treatment rates remain unclear and have
been debated in several studies [8, 20]. Concerns over
potential side effects of bisphosphonates and other osteo-
porosis treatments play an important role. Other barriers
could be the confusion regarding which physician is
responsible for treating osteoporosis in hip fracture patients
(orthopaedic surgeon? Internist/rheumatologist? Primary
care physician?), a lack of awareness by patients and
physicians regarding the treatment guidelines and the effi-
cacy of medications for osteoporosis following hip fracture
and the presence of comorbidities with resulting need for
polypharmacy. In fact, hip fracture is associated with
increase in drug use, as a result of a global deterioration of
health conditions [21]. However, recent literature data sug-
gest that the implementation of multidisciplinary integrated
models of care for patients with fragility fracture (e.g.
Fracture Liason Service) may optimize the identification of
Table 2 Distribution of clinical characteristics of 697 elderly patients with hip fractures
Characteristics All patients Siena Palermo Verona Naples
Comorbidities 672/697 (96.4) 243/249 (97.6) 97/100 (97.0) 140/143 (97.9) 192/205 (94.1)
Heart failure, n/total n (%) 499/697 (71.6) 144/249 (57.8) 87/100 (87.0) 106/143 (74.1) 162/205 (79.0)
Depression, n/total n (%) 73/697 (10.5) 31/249 (12.4) 5/100 (5.0) 19/143 (13.3) 18/205 (8.8)
Dementia, n/total n (%) 111/697 (38.0) 45/249 (18.1) 12/100 (12.0) 23/143 (16.1) 31/205 (15.1)
Diabetes, n/total n (%) 160/697 (23.0) 39/249 (14.9) 30/100 (30.0) 32/143 (22.4) 59/205 (28.8)
COPD, n/total n (%) 79/697 (11.3) 30/249 (12.0) 6/100 (6.0) 15/143 (10.5) 28/205 (13.7)
Chronic kidney disease, n/total n (%) 49/697 (7.0) 17/249 (6.8) 7/100 (7.0) 12/143 (8.4) 13/205 (6.3)
Rheumatoid arthritis, n/total n (%) 9/697 (1.3) 3/249 (1.2) 1/100 (1.0) 1/143 (0.7) 4/205 (2.0)
Breast cancer, n/total n (%) 17/697 (2.4) 10/249 (4.0) 2/100 (2.0) 1/143 (0.7) 5/205 (2.4)
Prostate cancer, n/total n (%) 13/697 (1.9) 9/249 (3.6) 1/100 (1.0) 1/143 (0.7) 2/205 (1.0)
Other cancers, n/total n (%) 57/697 (8.2) 25/249 (10.0) 5/100 (5.0) 10/143 (7.0) 7/205 (3.4)
Liver diseases, n/total n (%) 35/697 (5.0) 5/249 (5.0) 3/100 (3.0) 10/143 (7.0) 17/205 (8.3)
Inflammatory bowel disease, n/total n (%) 3/697 (0.4) 2/249 (0.8) 1/205 (0.5)
Hyperthyroidism, n/total n (%) 11/697 (1.6) 4/249 (1.6) 7/143 (4.9)
Hypothyroidism, n/total n (%) 62/697 (8.9) 24/249 (9.6) 13/100 (13.0) 12/143 (8.4) 13/205 (6.3)
Parkinson’s disease, n/total n (%) 28/697 (4.0) 12/249 (4.8) 3/100 (3.0) 5/143 (3.5) 8/205 (3.9)
Kidney stones, n/total n (%) 11/697 (1.6) 3/249 (1.2) 3/100 (3.0) 3/143 (2.1) 2/205 (1.0)
Medications 672/697 (96.4) 249/249 (100.0) 100/100 (100.0) 139/143 (97.2) 184/205 (89.8)
Antihypertensives, n/total n (%) 444/697 (63.7) 134/249 (53.8) 80/100 (80.0) 78/143 (54.5) 152/205 (74.1)
Diuretics, n/total n (%) 230/697 (33.0) 114/249 (45.8) 7/100 (7.0) 53/143 (37.1) 56/205 (27.3)
Antidepressants, n/total n (%) 80/697 (11.5) 33/249 (13.3) 6/100 (6.0) 22/143 (15.4) 19/205 (9.3)
Proton pump inhibitors, n/total n (%) 402/697 (57.7) 233/249 (93.6) 72/143 (50.3) 97/205 (47.3)
Glucocorticoids, n/total n (%) 22/697 (3.1) 17/249 (6.8) 5/205 (2.4)
Anticoagulants, n/total n (%) 30/697 (4.3) 1/249 (0.4) 1/100 (1.0) 15/143 (10.5) 13/205 (6.3)
Antiplatelets, n/total n (%) 232/697 (33.3) 96/249 (38.6) 32/100 (32.0) 45/143 (31.5) 59/205 (28.8)
Oral antidiabetic, n/total n (%) 100/697 (14.3) 26/249 (10.4) 15/100 (15.0) 25/143 (17.5) 34/205 (16.6)
Insulin, n/total n (%) 45/697 (6.5) 9/249 (3.6) 11/100 (11.0) 2/143 (1.4) 23/205 (11.2)
Antipsycotic, n/total n (%) 95/697 (13.6) 70/249 (28.1) 1/100 (1.0) 9/143 (6.3) 15/205 (7.3)
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patients at highest risk and make possible an adequate
pharmacological treatment in a larger number of patients
[22, 23]. Moreover, a recent study by Giannini et al. [24]
carried out in theVeneto region of Italy suggested that amore
comprehensive approach to osteoporosis managementmight
reduce hip fracture incidence in people aged 65 years or
over.
This study has shown a marked variability in the use of
osteoporosis medications across the four centres located in
different Italian geographical areas which could be
explained mainly by the different characteristics of the
departments and by differences in management.
Another important point is to understand which char-
acteristics of patients with hip fracture may influence the
decision to prescribe drugs for osteoporosis. Previous data
reported a higher proportion of comorbidities among BP
users compared with patients untreated with anti-osteo-
porotic drugs [9]. In agreement with previous reports, our
Fig. 2 Percentage of different
anti-osteoporotic treatments
before and after hip fracture
Table 3 Multiple logistic regression with regard to prescription for
anti-osteoporotic treatment
Odds ratio 95% CI p value
Age 1.176 0.762–1.815 0.463
Previous fractures 0.650 0.407–1.039 0.071
Sex 2.606 1.406–4.829 0.002
Previous osteoporotic therapy 6.215 2.978–12.969 0.001
Fig. 1 Percentage of patients
who received treatment for
osteoporosis before and after
the index hip fracture
Aging Clin Exp Res (2017) 29:1031–1037 1035
123
study has evidenced that male patients have less possibility
of receiving anti-osteoporotic treatments [25]. While a
precise explanation for the discrepancy in treatment rates
between women and men has not been identified, there is a
well-recognized tendency by both medical professionals
and patients to consider osteoporosis a disease of women.
Also, the use of anti-osteoporosis drugs before the index
hip fracture increased the likelihood of receiving anti-os-
teoporotic drugs at discharge. Moreover, in our study the
presence of comorbidities and the drugs taken before the
hip fracture did not seem to influence the prescription at
discharge.
Our study has some limitations. Firstly, the observa-
tional, retrospective design does not allow the establish-
ment of any causality relationships between the parameters.
Secondly, this study was unable to assess whether osteo-
porosis medication prescribed was in reality taken by the
patients. Thirdly, our results may have underestimated the
use of osteoporosis medication; in fact, it is possible that
some patients may have received a prescription for anti-
osteoporotic drugs directly from their primary care
physicians.
In conclusion, from our data it is evident that many
patients, even after sustaining a hip fracture, do not receive
anti-osteoporosis treatment, indicating that also in Italy
severe osteoporosis often remains untreated or under-
treated. Moreover, this study highlights the urgent need for
implementing new strategies in the management of hip
fracture patients in order to improve secondary prevention
of fragility fractures.
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